Lyell Immunopharma, Inc. (LYEL)


-0.02 (-1.35%)
Symbol LYEL
Price $1.46
Beta -1.385
Volume Avg. 0.72M
Market Cap 366.499M
Shares () -
52 Week Range 1.39-8.245
1y Target Est -
DCF Unlevered LYEL DCF ->
DCF Levered LYEL LDCF ->
ROE -33.79% Strong Sell
ROA -32.10% Strong Sell
Operating Margin -
Debt / Equity 8.17% Neutral
P/E -1.85 Sell
P/B 0.50 Neutral


Consensus EPS

Upgrades & Downgrades

Latest LYEL news

Dr. Lynn Seely M.D., Ph.D.
NASDAQ Global Select

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.